{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:18:31Z","timestamp":1788887911472,"version":"build-2803163510"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40263-026-01284-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:14:32Z","timestamp":1774944872000},"page":"761-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-8973","authenticated-orcid":false,"given":"Wolfgang","family":"L\u00f6scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-4408","authenticated-orcid":false,"given":"H. Steve","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-3722","authenticated-orcid":false,"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"8","key":"1284_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13(8):577\u201387.","journal-title":"Nat Rev Drug Discov"},{"key":"1284_CR2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.25813.1","volume":"9","author":"DC Swinney","year":"2020","unstructured":"Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. F1000Res. 2020;9:944.","journal-title":"F1000Res"},{"issue":"9","key":"1284_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","volume":"6","author":"E Perucca","year":"2007","unstructured":"Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793\u2013804.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1284_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrd2997","volume":"9","author":"M Bialer","year":"2010","unstructured":"Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68\u201382.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1284_CR5","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/biomedicines11061632","volume":"11","author":"MG Corrales-Hern\u00e1ndez","year":"2023","unstructured":"Corrales-Hern\u00e1ndez MG, Villarroel-Hagemann SK, Mendoza-Rodelo IE, Palacios-S\u00e1nchez L, Gaviria-Carrillo M, Buitrago-Ricaurte N, et al. Development of antiepileptic drugs throughout history: from serendipity to artificial intelligence. Biomedicines. 2023;11(6):1632.","journal-title":"Biomedicines"},{"issue":"6 Suppl","key":"1284_CR6","doi-asserted-by":"publisher","first-page":"24S","DOI":"10.1177\/1535759720948437","volume":"20","author":"JA French","year":"2020","unstructured":"French JA. Do you believe in magic (bullets)? Epilepsy Curr. 2020;20(6 Suppl):24S-26S.","journal-title":"Epilepsy Curr"},{"key":"1284_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35:935\u201363.","journal-title":"CNS Drugs"},{"issue":"4","key":"1284_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia. 2011;52(4):657\u201378.","journal-title":"Epilepsia"},{"issue":"17","key":"1284_CR9","doi-asserted-by":"publisher","first-page":"13143","DOI":"10.3390\/ijms241713143","volume":"24","author":"CS Yang","year":"2023","unstructured":"Yang CS, Wu MC, Lai MC, Wu SN, Huang CW. Identification of new antiseizure medication candidates in preclinical animal studies. Int J Mol Sci. 2023;24(17):13143.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1284_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40263-024-01130-y","volume":"38","author":"P Klein","year":"2024","unstructured":"Klein P, Friedman D, Kwan P. Recent advances in pharmacologic treatments of drug-resistant epilepsy: breakthrough in sight. CNS Drugs. 2024;38(12):949\u201360.","journal-title":"CNS Drugs"},{"issue":"3","key":"1284_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/epi.16832","volume":"62","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596\u2013614.","journal-title":"Epilepsia"},{"issue":"10","key":"1284_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/epi.14557","volume":"59","author":"M Bialer","year":"2018","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59(10):1811\u201341.","journal-title":"Epilepsia"},{"key":"1284_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.119.261222","volume":"372","author":"K Leclercq","year":"2020","unstructured":"Leclercq K, Matagne A, Provins L, Klitgaard H, Kaminski RM. Pharmacological profile of the antiepileptic drug candidate padsevonil\u2014characterization in rodent seizure and epilepsy models. J Pharmacol Exp Ther. 2020;372:11\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"1284_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/epi4.12656","volume":"7","author":"M Rademacher","year":"2022","unstructured":"Rademacher M, Toledo M, Van Paesschen W, Liow KK, Milanov IG, Esch ML, et al. Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: results from two double-blind, randomized, placebo-controlled trials. Epilepsia Open. 2022;7:758\u201370.","journal-title":"Epilepsia Open"},{"issue":"7","key":"1284_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","volume":"42","author":"W L\u00f6scher","year":"2017","unstructured":"L\u00f6scher W. Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res. 2017;42(7):1873\u201388.","journal-title":"Neurochem Res"},{"key":"1284_CR16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11064-017-2215-y","volume":"42","author":"RJ Porter","year":"2017","unstructured":"Porter RJ, Kupferberg HJ. The anticonvulsant screening program of the National Institute of Neurological Disorders and Stroke, NIH: history and contributions to clinical care in the twentieth century and beyond. Neurochem Res. 2017;42:1889\u201393.","journal-title":"Neurochem Res"},{"key":"1284_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","volume":"126","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157\u201384.","journal-title":"Epilepsy Res"},{"key":"1284_CR18","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1016\/S0040-4020(01)88100-X","volume":"42","author":"YM Choi","year":"1986","unstructured":"Choi YM, Kucharczyk N, Sofia RD. Metabolites of felbamate: synthesis of 2-(4-hydroxyphenyl)-1,3-propanediol dicarbamate, 2-phenyl-2-hydroxy-1,3-propanediol dicarbamate, and 2-phenyl-1,3-propanediol monocarbamate. Tetrahedron. 1986;42:6399\u2013404.","journal-title":"Tetrahedron"},{"issue":"1","key":"1284_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","volume":"83","author":"M Bialer","year":"2009","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83(1):1\u201343.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1284_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18920","volume":"9","author":"SM Melnick","year":"2023","unstructured":"Melnick SM, Shin Y, Glenn KJ. Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents. Heliyon. 2023;9(8):e18920.","journal-title":"Heliyon"},{"issue":"10","key":"1284_CR21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14656566.2025.2517352","volume":"26","author":"SM Melnick","year":"2025","unstructured":"Melnick SM, Misra SN, Kamin M, Ferrari L, Glenn KJ. Potential of cenobamate as a broad-spectrum antiseizure medication. Expert Opin Pharmacother. 2025;26(10):1177\u201389.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1284_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","volume":"103","author":"M Bialer","year":"2013","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103(1):2\u201330.","journal-title":"Epilepsy Res"},{"key":"1284_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107811","volume":"166","author":"KS Wilcox","year":"2020","unstructured":"Wilcox KS, West PJ, Metcalf CS. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"1284_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuropharm.2011.04.018","volume":"61","author":"J Francois","year":"2011","unstructured":"Francois J, Germe K, Ferrandon A, Koning E, Nehlig A. Carisbamate has powerful disease-modifying effects in the lithium-pilocarpine model of temporal lobe epilepsy. Neuropharmacology. 2011;61(1\u20132):313\u201328.","journal-title":"Neuropharmacology"},{"key":"1284_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109923","volume":"158","author":"W L\u00f6scher","year":"2024","unstructured":"L\u00f6scher W. Mammalian models of status epilepticus - their value and limitations. Epilepsy Behav. 2024;158:109923.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1284_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091233","volume":"12","author":"W L\u00f6scher","year":"2023","unstructured":"L\u00f6scher W, White HS. Animal models of drug-resistant epilepsy as tools for deciphering the cellular and molecular mechanisms of pharmacoresistance and discovering more effective treatments. Cells. 2023;12(9):1233.","journal-title":"Cells"},{"issue":"22","key":"1284_CR27","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"key":"1284_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1284_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"issue":"12","key":"1284_CR30","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","volume":"62","author":"MR Sperling","year":"2021","unstructured":"Sperling MR, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005\u201315.","journal-title":"Epilepsia"},{"issue":"10","key":"1284_CR31","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398.","journal-title":"Neurology"},{"issue":"1","key":"1284_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nurt.2006.11.016","volume":"4","author":"GP Novak","year":"2007","unstructured":"Novak GP, Kelley M, Zannikos P, Klein B. Carisbamate (RWJ-333369). Neurotherapeutics. 2007;4(1):106\u20139.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1284_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1124\/pr.110.003046","volume":"62","author":"W L\u00f6scher","year":"2010","unstructured":"L\u00f6scher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62(4):668\u2013700.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1284_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1517\/14728214.2010.492394","volume":"15","author":"W Nasreddine","year":"2010","unstructured":"Nasreddine W, Beydoun A, Atweh S, Abou-Khalil B. Emerging drugs for partial onset seizures. Expert Opin Emerg Drugs. 2010;15(3):415\u201331.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"20","key":"1284_CR35","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.wnl.0000334751.89859.7f","volume":"71","author":"E Faught","year":"2008","unstructured":"Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, et al. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008;71(20):1586\u201393.","journal-title":"Neurology"},{"issue":"3","key":"1284_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1528-1167.2009.02318.x","volume":"51","author":"MR Sperling","year":"2010","unstructured":"Sperling MR, Greenspan A, Cramer JA, Kwan P, K\u00e4lvi\u00e4inen R, Halford JJ, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010;51(3):333\u201343.","journal-title":"Epilepsia"},{"issue":"4","key":"1284_CR37","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1528-1167.2010.02960.x","volume":"52","author":"JJ Halford","year":"2011","unstructured":"Halford JJ, Ben Menachem E, Kwan P, Ness S, Schmitt J, Eerdekens M, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011;52(4):816\u201325.","journal-title":"Epilepsia"},{"issue":"1","key":"1284_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728214.2022.2059464","volume":"27","author":"AW Pong","year":"2022","unstructured":"Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, et al. Epilepsy: expert opinion on emerging drugs in phase 2\/3 clinical trials. Expert Opin Emerg Drugs. 2022;27(1):75\u201390.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1284_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2025.101242","volume":"56","author":"AW Pong","year":"2025","unstructured":"Pong AW. Expanding the toolkit: an update on the evolution of new therapies for Lennox\u2013Gastaut syndrome. Semin Pediatr Neurol. 2025;56:101242.","journal-title":"Semin Pediatr Neurol"},{"key":"1284_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231191000","volume":"16","author":"GJ Sills","year":"2023","unstructured":"Sills GJ. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. Ther Adv Neurol Disord. 2023;16:17562864231191000.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"1284_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","volume":"37","author":"E Perucca","year":"2023","unstructured":"Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755\u201379.","journal-title":"CNS Drugs"},{"key":"1284_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, et al. Positive allosteric modulation of GABA(A) receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.","journal-title":"Eur J Pharmacol"},{"key":"1284_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"855","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175\u201382.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"1284_CR44","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00424-024-02980-7","volume":"476","author":"P M\u00fcller","year":"2024","unstructured":"M\u00fcller P, Draguhn A, Egorov AV. Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. Pflugers Arch. 2024;476(10):1445\u201373.","journal-title":"Pflugers Arch"},{"issue":"1","key":"1284_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1535-7511.2007.00156.x","volume":"7","author":"CE Stafstrom","year":"2007","unstructured":"Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr. 2007;7(1):15\u201322.","journal-title":"Epilepsy Curr"},{"issue":"1","key":"1284_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1535759720973978","volume":"21","author":"ER Wengert","year":"2021","unstructured":"Wengert ER, Patel MK. The role of the persistent sodium current in epilepsy. Epilepsy Curr. 2021;21(1):40\u20137.","journal-title":"Epilepsy Curr"},{"key":"1284_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.","journal-title":"Neuropharmacology"},{"key":"1284_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.seizure.2025.11.010","volume":"134","author":"R Sankar","year":"2026","unstructured":"Sankar R, Ferrari L, Kamin M. Exploration of the mechanism of action of cenobamate. Seizure: Eur J Epilepsy. 2026;134:79\u201385.","journal-title":"Seizure: Eur J Epilepsy"},{"key":"1284_CR49","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI\u00ae): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61:2329\u201339.","journal-title":"Epilepsia"},{"key":"1284_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.seizure.2022.03.024","volume":"98","author":"YF Bai","year":"2022","unstructured":"Bai YF, Zeng C, Jia M, Xiao B. Molecular mechanisms of topiramate and its clinical value in epilepsy. Seizure. 2022;98:51\u20136.","journal-title":"Seizure"},{"issue":"3","key":"1284_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1528-1167.2008.01713.x","volume":"50","author":"RM Kaminski","year":"2009","unstructured":"Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia. 2009;50(3):387\u201397.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"1284_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","volume":"136","author":"RW Olsen","year":"2018","unstructured":"Olsen RW. GABA(A) receptor: positive and negative allosteric modulators. Neuropharmacology. 2018;136(Pt A):10\u201322.","journal-title":"Neuropharmacology"},{"key":"1284_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.261149","volume":"372","author":"M Wood","year":"2020","unstructured":"Wood M, Daniels V, Provins L, Wolff C, Kaminski RM, Gillard M. Pharmacological profile of the novel antiepileptic drug candidate padsevonil\u2014interactions with synaptic vesicle 2 proteins and the GABAA receptor. J Pharmacol Exp Ther. 2020;372:1\u201310.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1284_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","volume":"33","author":"P Skolnick","year":"2012","unstructured":"Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci. 2012;33(11):611\u201320.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"1284_CR55","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","volume":"39","author":"E Sigel","year":"2018","unstructured":"Sigel E, Ernst M. The benzodiazepine binding sites of GABA(A) receptors. Trends Pharmacol Sci. 2018;39(7):659\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"1284_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnmol.2017.00148","volume":"10","author":"O Bartholome","year":"2017","unstructured":"Bartholome O, Van den AP, S\u00e1nchez GJ, de la Brassinne BO, Leprince P, Franzen R, et al. Puzzling out synaptic vesicle 2 family members functions. Front Mol Neurosci. 2017;10:148.","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"1284_CR57","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1021\/acschemneuro.9b00351","volume":"10","author":"KA Stout","year":"2019","unstructured":"Stout KA, Dunn AR, Hoffman C, Miller GW. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance. ACS Chem Neurosci. 2019;10(9):3927\u201338.","journal-title":"ACS Chem Neurosci"},{"key":"1284_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi R, Arjmand S, Baerentzen SL, Gjedde A, Landau AM. Synaptic vesicle glycoprotein 2a: features and functions. Front Neurosci. 2022;16:864514.","journal-title":"Front Neurosci"},{"issue":"12","key":"1284_CR59","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41594-024-01430-3","volume":"31","author":"MM Bradberry","year":"2024","unstructured":"Bradberry MM, Chapman ER. Structural insights into SV2A and the mechanism of racetam anticonvulsants. Nat Struct Mol Biol. 2024;31(12):1818\u201320.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1284_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65781-1","volume":"16","author":"S Pidathala","year":"2025","unstructured":"Pidathala S, Chen X, Dai Y, Nguyen LN, Gorgulla C, Niu Y, et al. Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily. Nat Commun. 2025;16(1):10748.","journal-title":"Nat Commun"},{"issue":"5","key":"1284_CR61","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/epi.16497","volume":"61","author":"I Niespodziany","year":"2020","unstructured":"Niespodziany I, Ghisdal P, Mullier B, Wood M, Provins L, Kaminski RM, et al. Functional characterization of the antiepileptic drug candidate, padsevonil, on GABA(A) receptors. Epilepsia. 2020;61(5):914\u201323.","journal-title":"Epilepsia"},{"issue":"5733","key":"1284_CR62","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/281688a0","volume":"281","author":"SM Paul","year":"1979","unstructured":"Paul SM, Syapin PJ, Paugh BA, Moncada V, Skolnick P. Correlation between benzodiazepine receptor occupation and anticonvulsant effects of diazepam. Nature. 1979;281(5733):688\u20139.","journal-title":"Nature"},{"key":"1284_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(85)90368-1","volume":"114","author":"W L\u00f6scher","year":"1985","unstructured":"L\u00f6scher W, Schneider H, Kehr W. Evaluation of different b-carbolines in Mongolian gerbils with reflex epilepsy. Eur J Pharmacol. 1985;114:261\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1284_CR64","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF02253530","volume":"111","author":"JR Martin","year":"1993","unstructured":"Martin JR, Schoch P, Jenck F, Moreau JL, Haefely WE. Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology. 1993;111(4):415\u201322.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1284_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40263-013-0129-z","volume":"28","author":"C Rundfeldt","year":"2014","unstructured":"Rundfeldt C, L\u00f6scher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014;28(1):29\u201343.","journal-title":"CNS Drugs"},{"issue":"3","key":"1284_CR66","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0022-3565(25)11126-9","volume":"261","author":"M Facklam","year":"1992","unstructured":"Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau JL, et al. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 1992;261(3):1113\u201321.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"1284_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1\u20133):36\u201344.","journal-title":"Eur J Pharmacol"},{"key":"1284_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","volume":"232","author":"W L\u00f6scher","year":"1993","unstructured":"L\u00f6scher W, H\u00f6nack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147\u201358.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1284_CR69","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s43440-024-00628-y","volume":"76","author":"S Quinlan","year":"2024","unstructured":"Quinlan S, Witherspoon E, Forcelli PA. Padsevonil suppresses seizures without inducing cell death in neonatal rats. Pharmacol Rep. 2024;76(5):1055\u201366.","journal-title":"Pharmacol Rep"},{"key":"1284_CR70","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1749-6632.2003.tb07517.x","volume":"993","author":"P Bittigau","year":"2003","unstructured":"Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci. 2003;993:103\u201314.","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"1284_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa183","volume":"2","author":"P Muglia","year":"2020","unstructured":"Muglia P, Hannestad J, Brandt C, DeBruyn S, Germani M, Lacroix B, et al. Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach. Brain Commun. 2020;2(2):fcaa183.","journal-title":"Brain Commun"},{"key":"1284_CR72","unstructured":"Van Paesschen W, Toledo M, Brandt C, Steinhoff BJ. Dissecting the heterogeneous clinical response to padsevonil in adults with drug-resistant focal seizures: post hoc responder analysis of a proof-of-concept trial. American Epilepsy Society (AES), 2018 Annual Meeting, New Orleans, Louisiana, USA, Abstract number 1.289. https:\/\/aesnet.org\/abstractslisting\/dissecting-the-heterogeneous-clinical-response-to-padsevonil-in-adults-with-drug-resistant-focal-seizures--post-hoc-responder-analysis-of-a-proof-of-concept-trial. Accessed 26 Feb 2026."},{"key":"1284_CR73","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","volume":"20","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359\u201368.","journal-title":"Seizure"},{"key":"1284_CR74","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","volume":"47","author":"ME Barton","year":"2001","unstructured":"Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217\u201328.","journal-title":"Epilepsy Res"},{"key":"1284_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0014-4886(86)90160-3","volume":"93","author":"W L\u00f6scher","year":"1986","unstructured":"L\u00f6scher W, J\u00e4ckel R, Czuczwar SJ. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp Neurol. 1986;93:211\u201326.","journal-title":"Exp Neurol"},{"issue":"11","key":"1284_CR76","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","volume":"30","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic vesicle glycoprotein 2a ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055\u201377.","journal-title":"CNS Drugs"},{"key":"1284_CR77","first-page":"1","volume":"10","author":"P Klein","year":"2018","unstructured":"Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of Brivaracetam. Clin Pharmacol Ther. 2018;10:1\u201322.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1284_CR78","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138.","journal-title":"Epilepsia"},{"key":"1284_CR79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","volume":"61","author":"M Hirsch","year":"2018","unstructured":"Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98\u2013103.","journal-title":"Seizure"},{"issue":"12","key":"1284_CR80","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1007\/s00415-023-11959-w","volume":"270","author":"LV Watkins","year":"2023","unstructured":"Watkins LV, Dunstall H, Musicha C, Lawthom C, John K, Bright C, et al. Rapid switching from Levetiracetam to Brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study. J Neurol. 2023;270(12):5889\u2013902.","journal-title":"J Neurol"},{"key":"1284_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00125","volume":"9","author":"J Correa-Basurto","year":"2015","unstructured":"Correa-Basurto J, Cuevas-Hern\u00e1ndez RI, Phillips-Farf\u00e1n BV, Martinez-Archundia M, Romo-Mancillas A, Ramirez-Salinas GL, et al. Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Front Cell Neurosci. 2015;9:125.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"1284_CR82","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/epi.13638","volume":"58","author":"MD Wood","year":"2017","unstructured":"Wood MD, Gillard M. Evidence for a differential interaction of Brivaracetam and Levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2017;58(2):255\u201362.","journal-title":"Epilepsia"},{"issue":"9","key":"1284_CR83","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1111\/epi.14532","volume":"59","author":"MD Wood","year":"2018","unstructured":"Wood MD, Sands ZA, Vandenplas C, Gillard M. Further evidence for a differential interaction of Brivaracetam and Levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018;59(9):e147\u201351.","journal-title":"Epilepsia"},{"key":"1284_CR84","first-page":"379","volume":"47","author":"W Haefely","year":"1992","unstructured":"Haefely W, Facklam M, Schoch P, Martin JR, Bonetti EP, Moreau JL, et al. Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders. Adv Biochem Psychopharmacol. 1992;47:379\u201394.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"1284_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-026-01281-0","author":"W L\u00f6scher","year":"2026","unstructured":"L\u00f6scher W, Rundfeldt C, Trinka E, Koepp M, Klein P. Seletracetam re-visited: a missed opportunity for effective epilepsy therapy. CNS Drugs. 2026. https:\/\/doi.org\/10.1007\/s40263-026-01281-0.","journal-title":"CNS Drugs"},{"issue":"4","key":"1284_CR86","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1528-1167.2008.01915.x","volume":"50","author":"G Martella","year":"2009","unstructured":"Martella G, Bonsi P, Sciamanna G, Platania P, Madeo G, Tassone A, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009;50(4):702\u201310.","journal-title":"Epilepsia"},{"key":"1284_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110241","volume":"164","author":"D Kasteleijn-Nolst Trenit\u00e9","year":"2025","unstructured":"Kasteleijn-Nolst Trenit\u00e9 D, Stockis A, Hirsch E, Genton P, Abou-Khalil BW, French JA, et al. A multicenter phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients. Epilepsy Behav. 2025;164:110241.","journal-title":"Epilepsy Behav"},{"key":"1284_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106369","volume":"167","author":"P Klein","year":"2020","unstructured":"Klein P, McLachlan R, Foris K, Nondonfaz X, Elmoufti S, Dimova S, et al. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: post-hoc analysis of a randomized, placebo-controlled trial. Epilepsy Res. 2020;167:106369.","journal-title":"Epilepsy Res"},{"issue":"1","key":"1284_CR89","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","volume":"70","author":"Y Schiller","year":"2008","unstructured":"Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008;70(1):54\u201365.","journal-title":"Neurology"},{"key":"1284_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106952","volume":"184","author":"B Abou-Khalil","year":"2022","unstructured":"Abou-Khalil B, Aboumatar S, Klein P, Krauss GL, Sperling MR, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184:106952.","journal-title":"Epilepsy Res"},{"key":"1284_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107796","volume":"116","author":"R Elizebath","year":"2021","unstructured":"Elizebath R, Zhang E, Coe P, Gutierrez EG, Yang J, Krauss GL. Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment. Epilepsy Behav. 2021;116:107796.","journal-title":"Epilepsy Behav"},{"key":"1284_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"\u00c0 Beltr\u00e1n-Corbellini","year":"2023","unstructured":"Beltr\u00e1n-Corbellini \u00c0, Romeral-Jim\u00e9nez M, Mayo P, S\u00e1nchez-Miranda R, Iruzubieta P, Chico-Garc\u00eda JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71\u20137.","journal-title":"Seizure"},{"issue":"3","key":"1284_CR93","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, G\u00f3mez-Ib\u00e1nez A, Garc\u00e9s M, Serrano-Castro P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918\u201329.","journal-title":"Epilepsia Open"},{"issue":"5","key":"1284_CR94","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/epi.17549","volume":"64","author":"J Pena-Ceballos","year":"2023","unstructured":"Pena-Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study. Epilepsia. 2023;64(5):1225\u201335.","journal-title":"Epilepsia"},{"issue":"4","key":"1284_CR95","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/epi4.12959","volume":"9","author":"JJ Rodr\u00edguez-Uranga","year":"2024","unstructured":"Rodr\u00edguez-Uranga JJ, S\u00e1nchez-Caro JM, Hariramani RR. Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain. Epilepsia Open. 2024;9(4):1345\u201356.","journal-title":"Epilepsia Open"},{"issue":"8","key":"1284_CR96","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s10072-025-08174-y","volume":"46","author":"CE Gjerulfsen","year":"2025","unstructured":"Gjerulfsen CE, Juhl S, Mieszczanek KM, Spanil\u00e1 L, Thygesen KS, Pavbro A, et al. Cenobamate as add-on treatment in ultra-refractory focal epilepsy: real-world results from The Danish Epilepsy Centre, Dianalund, Denmark. Neurol Sci. 2025;46(8):3875\u201384.","journal-title":"Neurol Sci"},{"issue":"10","key":"1284_CR97","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","volume":"271","author":"S Lauxmann","year":"2024","unstructured":"Lauxmann S, Heuer D, Heckelmann J, Fischer FP, Schreiber M, Schriewer E, et al. Cenobamate: real-world data from a retrospective multicenter study. J Neurol. 2024;271(10):6596\u2013604.","journal-title":"J Neurol"},{"issue":"3","key":"1284_CR98","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/epi.17874","volume":"65","author":"Y Novitskaya","year":"2024","unstructured":"Novitskaya Y, Sch\u00c3\u00bctz E, Metternich B, Schulze-Bonhage A, Hirsch M. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2024;65(3):630\u201340.","journal-title":"Epilepsia"},{"key":"1284_CR99","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.seizure.2024.12.010","volume":"125","author":"E Martinez-Lizana","year":"2025","unstructured":"Martinez-Lizana E, Brandt A, Novitskaya Y, Hirsch M, Schulze-Bonhage A. Impact of lifetime antiepileptic drug history on cenobamate efficacy in adults with focal epilepsy. Seizure. 2025;125:94\u20138.","journal-title":"Seizure"},{"issue":"Pt 1","key":"1284_CR100","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/brain\/awh682","volume":"129","author":"S Remy","year":"2006","unstructured":"Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006;129(Pt 1):18\u201335.","journal-title":"Brain"},{"key":"1284_CR101","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606\u201338.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1284_CR102","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11307-020-01488-7","volume":"22","author":"ME Serrano","year":"2020","unstructured":"Serrano ME, Bahri MA, Becker G, Seret A, Germonpr\u00e9 C, Lemaire C, et al. Exploring with [18F]UCB-H the in vivo variations in SV2A expression through the Kainic Acid rat model of Temporal Lobe epilepsy. Mol Imaging Biol. 2020;22(5):1197\u2013207.","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"1284_CR103","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1111\/epi.16653","volume":"61","author":"SJ Finnema","year":"2020","unstructured":"Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, et al. Reduced synaptic vesicle protein 2A binding in Temporal Lobe epilepsy: a [(11) C]UCB-J Positron Emission Tomography study. Epilepsia. 2020;61(10):2183\u201393.","journal-title":"Epilepsia"},{"key":"1284_CR104","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1111\/bph.70076","volume":"182","author":"M Guignet","year":"2025","unstructured":"Guignet M, Vuong J, Uribe N, Ballapapinan T, White HS. Challenging the preclinical paradigm: adverse effects of antiseizure medicines in male rats with drug-resistant epilepsy. Br J Pharmacol. 2025;182:4314\u201326.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1284_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.70020","volume":"4","author":"DS Reddy","year":"2024","unstructured":"Reddy DS, Vadassery A, Ramakrishnan S, Singh T, Clossen B, Wu X. Kindling models of epileptogenesis for developing disease-modifying drugs for epilepsy. Curr Protoc. 2024;4(10):e70020.","journal-title":"Curr Protoc"},{"issue":"1","key":"1284_CR106","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0306-4522(02)00064-7","volume":"112","author":"V Riban","year":"2002","unstructured":"Riban V, Bouilleret V, Pham L, Fritschy JM, Marescaux C, Depaulis A. Evolution of hippocampal epileptic activity during the development of Hippocampal Sclerosis in a mouse model of Temporal Lobe epilepsy. Neuroscience. 2002;112(1):101\u201311.","journal-title":"Neuroscience"},{"key":"1284_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/epi4.2","volume":"1","author":"F Twele","year":"2016","unstructured":"Twele F, T\u00f6llner K, Bankstahl M, L\u00f6scher W. The effects of carbamazepine in the intrahippocampal Kainate model of Temporal Lobe epilepsy depend on seizure definition and mouse strain. Epilepsia Open. 2016;1:45\u201360.","journal-title":"Epilepsia Open"},{"key":"1284_CR108","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/epi4.12044","volume":"2","author":"F Twele","year":"2017","unstructured":"Twele F, Schidlitzki A, T\u00f6llner K, L\u00f6scher W. The intrahippocampal kainate mouse model of mesial temporal lobe epilepsy: lack of electrographic seizure-like events in sham controls. Epilepsia Open. 2017;2:180\u20137.","journal-title":"Epilepsia Open"},{"issue":"1","key":"1284_CR109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/epi.16406","volume":"61","author":"L Welzel","year":"2020","unstructured":"Welzel L, Schidlitzki A, Twele F, Anjum M, L\u00f6scher W. A face-to-face comparison of the intra-amygdala and intrahippocampal kainate mouse models of mesial temporal lobe epilepsy and their utility for testing novel therapies. Epilepsia. 2020;61(1):157\u201370.","journal-title":"Epilepsia"},{"key":"1284_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113954","volume":"349","author":"PJ West","year":"2022","unstructured":"West PJ, Thomson K, Billingsley P, Pruess T, Rueda C, Saunders GW, et al. Spontaneous recurrent seizures in an intra-amygdala kainate microinjection model of temporal lobe epilepsy are differentially sensitive to antiseizure drugs. Exp Neurol. 2022;349:113954.","journal-title":"Exp Neurol"},{"key":"1284_CR111","doi-asserted-by":"publisher","first-page":"1308478","DOI":"10.3389\/fphar.2023.1308478","volume":"14","author":"O Mamad","year":"2023","unstructured":"Mamad O, Heiland M, Lindner AU, Hill TDM, Ronroy RM, Rentrup K, et al. Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice. Front Pharmacol. 2023;14:1308478.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1284_CR112","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526\u201348.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1284_CR113","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","volume":"68","author":"MJ Brodie","year":"2007","unstructured":"Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402\u20138.","journal-title":"Neurology"},{"issue":"7","key":"1284_CR114","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1284_CR115","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2012.236","volume":"93","author":"DC Swinney","year":"2013","unstructured":"Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther. 2013;93(4):299\u2013301.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1284_CR116","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531\u201343.","journal-title":"Nat Rev Drug Discov"},{"key":"1284_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.730257","volume":"12","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W. Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy. Front Pharmacol. 2021;12:730257.","journal-title":"Front Pharmacol"},{"key":"1284_CR118","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W L\u00f6scher","year":"2002","unstructured":"L\u00f6scher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669\u201394.","journal-title":"CNS Drugs"},{"key":"1284_CR119","first-page":"17","volume":"4","author":"E Hargrave-Thomas","year":"2012","unstructured":"Hargrave-Thomas E, Yu B, Reynisson J. The effect of serendipity in drug discovery and development. Chem N Z. 2012;4:17\u201320.","journal-title":"Chem N Z"},{"key":"1284_CR120","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1459.1000e121","volume":"3","author":"AA Baumeister","year":"2013","unstructured":"Baumeister AA, Pow JL, Henderson K, L\u00f3pez-Mu\u00f1oz F. On the exploitation of serendipity in drug discovery. Clin Exp Pharmacol. 2013;3:1000e121.","journal-title":"Clin Exp Pharmacol"},{"issue":"8","key":"1284_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103648","volume":"28","author":"DC Thompson","year":"2023","unstructured":"Thompson DC, Copeland SM. Serendipity in research and development: the promise of putting into place patterns for paying attention. Drug Discov Today. 2023;28(8):103648.","journal-title":"Drug Discov Today"},{"issue":"11","key":"1284_CR122","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1111\/j.1528-1167.2012.03541.x","volume":"53","author":"M Simonato","year":"2012","unstructured":"Simonato M, L\u00f6scher W, Cole AJ, Dudek FE, Engel J Jr., Kaminski RM, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia. 2012;53(11):1860\u20137.","journal-title":"Epilepsia"},{"issue":"6","key":"1284_CR123","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/epi.13764","volume":"58","author":"CS Metcalf","year":"2017","unstructured":"Metcalf CS, West PJ, Thomson KE, Edwards SF, Smith MD, White HS, et al. Development and pharmacologic characterization of the rat 6 Hz model of partial seizures. Epilepsia. 2017;58(6):1073\u201384.","journal-title":"Epilepsia"},{"key":"1284_CR124","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.yebeh.2017.05.040","volume":"73","author":"W L\u00f6scher","year":"2017","unstructured":"L\u00f6scher W, Ferland RJ, Ferraro TN. The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy. Epilepsy Behav. 2017;73:214\u201335.","journal-title":"Epilepsy Behav"},{"issue":"12","key":"1284_CR125","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328.","journal-title":"Epilepsia"},{"key":"1284_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176222","volume":"962","author":"A Leo","year":"2024","unstructured":"Leo A, Bosco F, Guarnieri L, De Sarro C, Rania V, Gallelli L, et al. Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA\/2 mouse model of reflex epilepsy. Eur J Pharmacol. 2024;962:176222.","journal-title":"Eur J Pharmacol"},{"key":"1284_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1223074","volume":"14","author":"F Bosco","year":"2023","unstructured":"Bosco F, Guarnieri L, Leo A, Tallarico M, Gallelli L, Rania V, et al. Audiogenic epileptic DBA\/2 mice strain as a model of genetic reflex seizures and SUDEP. Front Neurol. 2023;14:1223074.","journal-title":"Front Neurol"},{"key":"1284_CR128","unstructured":"Klein BD, Smith MD, White HS. The novel neuromodulator carisbamate delays the acquisition of rat amygdala kindling and maintains acute antiepileptic activity when evaluated in postkindled rats. American Epilepsy Society (AES) Annual Meeting 2007; Philadelpha, PA, USA. Abstract number 3.322. https:\/\/aesnet.org\/abstractslisting\/the-novel-neuromodulator-carisbamate-delays-the-acquisition-of-rat-amygdala-kindling-and-maintains-acute-antiepileptic-activity-when-evaluated-in-post-kindled-rats-. Accessed 26 Feb 2026."},{"issue":"3","key":"1284_CR129","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1528-1167.2007.01278.x","volume":"49","author":"J Francois","year":"2008","unstructured":"Francois J, Boehrer A, Nehlig A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia. 2008;49(3):393\u20139.","journal-title":"Epilepsia"},{"key":"1284_CR130","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1528-1157.1986.tb03497.x","volume":"27","author":"EA Swinyard","year":"1986","unstructured":"Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia. 1986;27:27\u201334.","journal-title":"Epilepsia"},{"issue":"3","key":"1284_CR131","first-page":"335","volume":"79","author":"RD Sofia","year":"1993","unstructured":"Sofia RD, Gordon R, Gels M, Diamantis W. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Res Commun Chem Pathol Pharmacol. 1993;79(3):335\u201341.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"1284_CR132","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0920-1211(97)01021-8","volume":"27","author":"HH Frey","year":"1997","unstructured":"Frey HH, Bartels I. Felbamate and meprobamate: a comparison of their anticonvulsant properties. Epilepsy Res. 1997;27:151\u201364.","journal-title":"Epilepsy Res"},{"key":"1284_CR133","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/j.1528-1157.1997.tb01212.x","volume":"38","author":"P Wlaz","year":"1997","unstructured":"Wlaz P, L\u00f6scher W. Anticonvulsant activity of felbamate in amygdala kindling model of temporal lobe epilepsy in rat. Epilepsia. 1997;38:1167\u201372.","journal-title":"Epilepsia"},{"issue":"3","key":"1284_CR134","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.11.001","volume":"68","author":"MG Vartanian","year":"2006","unstructured":"Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006;68(3):189\u2013205.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1284_CR135","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00213-009-1682-5","volume":"207","author":"GA Higgins","year":"2010","unstructured":"Higgins GA, Breysse N, Undzys E, Derksen DR, Jeffrey M, Scott BW, et al. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology. 2010;207(4):513\u201327.","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"1284_CR136","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eplepsyres.2010.09.002","volume":"92","author":"NM Rowley","year":"2010","unstructured":"Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res. 2010;92(2\u20133):163\u20139.","journal-title":"Epilepsy Res"},{"key":"1284_CR137","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0920-1211(97)00031-4","volume":"28","author":"NO Dalby","year":"1997","unstructured":"Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res. 1997;28:63\u201372.","journal-title":"Epilepsy Res"},{"issue":"Suppl 1","key":"1284_CR138","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3-9.","journal-title":"Epilepsia"},{"issue":"1","key":"1284_CR139","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1528-1157.2003.32902.x","volume":"44","author":"MA Rigoulot","year":"2003","unstructured":"Rigoulot MA, Boehrer A, Nehlig A. Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia. 2003;44(1):14\u20139.","journal-title":"Epilepsia"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01284-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01284-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01284-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:03:08Z","timestamp":1779807788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01284-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01284-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"W. L\u00f6scher is a member of the External Consultant Board of the NINDS ETSP program. He is co-founder and CSO of PrevEp, Inc. (Bethesda, MD). He has received in the past 5 years consultancy fees from Lundbeck, Angelini, Clexio, Selene, Axonis, SynapCell, Sintetica, ND Capital, Atlas Venture, Cogent Biosolutions, Ovid, Idorsia, and Addex. Pavel Klein has served as a consultant, advisory board member or speaker (2020\u20132025) for Abbott,\u00a0Angelini Pharma, Aquestive Therapeutics, Arvelle Therapeutics,\u00a0Aucta Pharmaceuticals, Dr. Reddy's, Eisai, GRIN Therapeutics, Jazz Pharmaceuticals, Longboard Pharmaceuticals, Neurelis, Neurona Therapeutics, Paladin Pharma, SK Life Science, Sunovion, UCB Pharma, UNEEG, UniQure, and Xenon Pharma; is a member of the Data and Safety Monitoring Board for Neurona Therapeutics; and is a member of Medical Advisory Board of Stratus and of the Scientific Advisory Boards of OB Pharma and of NEUmirna; is the CEO of PrevEp, Inc.;\u00a0and has received research support from CURE\/Department of Defense and from the NIH\/SBIR. H.S. White has received grant funding from Neurelis and consultant fees from BioPharm Solutions and JAZZ Pharmaceuticals, and speaker honoraria from SK Life Sciences, Takeda, and UCB Pharma. He is also co-founder of NeuroAdjuvants, Inc., Salt Lake City, UT.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current review are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"W.L.: conceptualization, writing\u2014original draft, visualization, writing\u2014reviewing and editing. P.K. and H.S.W.: writing\u2014reviewing and editing. All authors reviewed and approved the final paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}